8:30 a.m.    Check-in ~ Continental Breakfast

8:55 a.m.    Opening remarks – Julia Babensee and Susan Thomas, Symposium Co-Chairs

Session I
Session Chair – Susan Thomas

9:00 a.m.    Keynote Presentation - “Translating Prime Editing into Genetic Medicines” - Ann Lee, Chief Technical Officer, Prime Medicine

10:00 a.m.    Break  

10:30 a.m.    “ImmuneEngineering Autologous Adaptive Cell Therapy (AACT) Manufactured at the Point of Care” - John Powderly, MD, Founder and President, Carolina BioOncology Institute, BioCytics Human Applications Lab

11:15 a.m.    “An Adventure in Developing Lymphatic Therapies for the Treatment of Rheumatoid Arthritis and Cutaneous T Cell Lymphoma” - Russell “Rusty” Ross, Chief Technical Officer, Sofusa™ Business Unit, Sorrento Therapeutics

12:00 p.m.    Poster Session / Lunch – Nerem Atrium

Session II
Session Chair – Julia Babensee

1:00 p.m.    "A Scientist’s View on Navigating Regulatory Development of a Personalized Cancer Vaccine Immunotherapy Through Early Clinical Trials" - Kristen Jacobsen, Senior Scientist, Metaclipse Therapeutics Corporation

1:45 p.m.    "Developing γδT Cells as an Allogeneic Cell Therapy Platform” - Brian Petrich, Director of Oncology, Expression Therapeutics

2:30 p.m.    Break

2:45 p.m.     “Nonviral Manufacturing of Genome-edited, Immune Cell Therapies” - Krishanu Saha, Professor of Biomedical Engineering & Retina Research Foundation Kathryn and Latimer Murfee Chair, University of Wisconsin-Madison 

3:30 p.m.    Final remarks ~ Adjourn 

Thank you to Georgia Tech's Office of the Executive Vice President for Research for their support of this meeting through the NIH T32 Training Grant "Research Program in Immunoengineering," and for the support from the Parker H. Petit Institute for Bioengineering and Bioscience.